Elysisgen, a partner of REYON Pharmaceutical(102460), will present 44-week interim results for the mid-dose (cohort 2) of the phase 1/2a clinical trial of the gene therapy "NG101" for wet age-related macular degeneration (wAMD) at the American Society of Retina Specialists (ASRS 2026) in Montreal, Canada, starting on the 15th (local time).
Elysisgen said it will join a session with global big pharma Eli Lilly and Company to discuss the latest clinical results in next-generation therapeutics and plans to present its gene therapy pipeline. ASRS is one of the most prestigious societies attended by retina specialists and researchers worldwide.
The presentation will be given by principal investigator (PI) Curtis, a professor in the Department of Ophthalmology and Vision Sciences at the University of Toronto in Canada. Curtis, a world-renowned authority in retinal, macular, and vitreoretinal diseases, is expected to detail the clinical value of NG101 in the presentation.
Elysisgen expects the mid-dose (cohort 2) clinical presentation to demonstrate NG101's consistency as a next-generation therapy. Earlier, in May, Elysisgen disclosed the performance of the low-dose (cohort 1) data at the Association for Research in Vision and Ophthalmology (ARVO).
At that time, subjects given the low dose of NG101 saw their additional injection frequency over 52 weeks decrease by about 89% compared with the conventional regimen (annual average 9.8 times → 1.1 times), and 83% of all subjects maintained vision with one or fewer injections.
Elysisgen said, "It is thanks to the conference review committee judging NG101's clinical data and technical value to be a main agenda item of the meeting," adding, "It means Elysisgen's technological capabilities have been recognized in the global gene therapy market."
Based on a co-development agreement signed with Elysisgen in 2020, REYON Pharmaceutical is responsible for global manufacturing and supply of NG101. Through its GMP facilities at the Chungju plant, REYON Pharmaceutical has established a production system for the future commercialization of NG101 and its entry into global markets.